Allele-specific genomic targeting by CRISPR is a versatile strategy that has been increasingly exploited not only in treating inherited dominant diseases and mutation-driven cancers, but also in other important fields such as genome imprinting, haploinsufficiency, and genome loci imaging. Despite its tremendous utilities, few bioinformatic tools have been implemented for the allele-specific purpose of CRISPR. We thus developed AsCRISPR (Allele-specific CRISPR), a comprehensive web tool to aid the design of short-guide RNA (sgRNA) sequences that can discriminate between alleles. AsCRISPR allows users to analyze both their own identified variants and heterozygous single nucleotide polymorphisms and, importantly, output the candidate sgRNAs and their quality control information. To facilitate targeting dominant diseases, AsCRISPR analyzed dominant single nucleotide variants (SNVs) retrieved from ClinVar and OMIM databases, and generated a dominant database of candidate-discriminating sgRNAs that may specifically target the alternative allele for each dominant SNV site. Moreover, a validated database was established, which manually curated the discriminating sgRNAs that were experimentally validated in the mounting literature for multiple allele-specific purposes.
Get full access to this article
View all access options for this article.
References
1.
MongaI, QureshiA, ThakurN, et al.ASPsiRNA: a resource of ASP-siRNAs having therapeutic potential for human genetic disorders and algorithm for prediction of their inhibitory efficacy. G3 (Bethesda), 2017; 7:2931–2943. DOI: 10.1534/g3.117.044024.
WuJ, TangB, TangY. Allele-specific genome targeting in the development of precision medicine. Theranostics, 2020; 10:3118–3137. DOI: 10.7150/thno.43298.
4.
CongL, RanFA, CoxD, et al.Multiplex genome engineering using CRISPR/Cas systems. Science, 2013; 339:819–823. DOI: 10.1126/science.1231143.
5.
BurnightER, GuptaM, WileyLA, et al.Using CRISPR-Cas9 to generate gene-corrected autologous iPSCs for the treatment of inherited retinal degeneration. Mol Ther, 2017; 25:1999–2013. DOI: 10.1016/j.ymthe.2017.05.015.
6.
GiannelliSG, LuoniM, CastoldiV, et al.Cas9/sgRNA selective targeting of the P23H rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal. AAV9.PHP.B-based delivery. Hum Mol Genet, 2018;27:761–779. DOI: 10.1093/hmg/ddx438.
7.
LiP, KleinstiverBP, LeonMY, et al.Allele-specific CRISPR-Cas9 genome editing of the single-base P23H mutation for rhodopsin-associated dominant retinitis pigmentosa. CRISPR J, 2018; 1:55–64. DOI: 10.1089/crispr.2017.0009.
8.
BakondiB, LvW, LuB, et al.In vivo CRISPR/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa. Mol Ther, 2016; 24:556–563. DOI: 10.1038/mt.2015.220.
GyorgyB, Nist-LundC, PanB, et al.Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss. Nat Med, 2019; 25:1123–1130. DOI: 10.1038/s41591-019-0500-9.
11.
GaoQ, OuyangW, KangB, et al.Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression. Theranostics, 2020; 10:5137–5153. DOI: 10.7150/thno.42325.
12.
LentschE, LiL, PfefferS, et al.CRISPR/Cas9-mediated knock-out of Kras(G12D) mutated pancreatic cancer cell lines. Int J Mol Sci, 2019; 20. DOI: 10.3390/ijms20225706.
13.
KooT, YoonAR, ChoHY, et al.Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression. Nucleic Acids Res, 2017; 45:7897–7908. DOI: 10.1093/nar/gkx490.
14.
BashtrykovP, KungulovskiG, and JeltschA. Correction of aberrant imprinting by allele-specific epigenome editing. Clin Pharmacol Ther, 2016; 99:482–484. DOI: 10.1002/cpt.295.
15.
MatharuN, RattanasophaS, TamuraS, et al.CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. Science, 2019; 363. DOI: 10.1126/science.aau0629.
16.
XuH, WangB, OnoM, et al.Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell, 2019; 24:566–578.e7. DOI: 10.1016/j.stem.2019.02.005.
17.
MonteysAM, EbanksSA, KeiserMS, et al.CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol Ther, 2017; 25:12–23. DOI: 10.1016/j.ymthe.2016.11.010.
18.
ShinJW, KimKH, ChaoMJ, et al.Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9. Hum Mol Genet, 2016; 25:4566–4576. DOI: 10.1093/hmg/ddw286.
19.
LandrumMJ, LeeJM, BensonM, et al.ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res, 2018; 46:D1062–D1067. DOI: 10.1093/nar/gkx1153.
20.
AmbergerJS, BocchiniCA, SchiettecatteF, et al.OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res 2015;43(Database issue):D789–798. DOI: 10.1093/nar/gku1205.
21.
StreckerJ, JonesS, KoopalB, et al.Engineering of CRISPR-Cas12b for human genome editing. Nat Commun, 2019; 10:212. DOI: 10.1038/s41467-018-08224-4.
22.
TengF, CuiT, FengG, et al.Repurposing CRISPR-Cas12b for mammalian genome engineering. Cell Discov, 2018; 4:63. DOI: 10.1038/s41421-018-0069-3.
23.
LiuJJ, OrlovaN, OakesBL, et al.CasX enzymes comprise a distinct family of RNA-guided genome editors. Nature, 2019; 566:218–223. DOI: 10.1038/s41586-019-0908-x.
24.
HsuPD, ScottDA, WeinsteinJA, et al.DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol, 2013; 31:827–832. DOI: 10.1038/nbt.2647.
25.
JiangW, BikardD, CoxD, et al.RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol, 2013; 31:233–239. DOI: 10.1038/nbt.2508.
26.
HaeusslerM, SchonigK, EckertH, et al.Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol, 2016; 17:148. DOI: 10.1186/s13059-016-1012-2.
27.
XuH, XiaoT, ChenCH, et al.Sequence determinants of improved CRISPR sgRNA design. Genome Res, 2015; 25:1147–1157. DOI: 10.1101/gr.191452.115.
28.
DoenchJG, FusiN, SullenderM, et al.Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol, 2016; 34:184–191. DOI: 10.1038/nbt.3437.
29.
Moreno-MateosMA, VejnarCE, BeaudoinJD, et al.CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. Nat Methods, 2015; 12:982–988. DOI: 10.1038/nmeth.3543.
30.
ListgartenJ, WeinsteinM, KleinstiverBP, et al.Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs. Nat Biomed Eng, 2018; 2:38–47. DOI: 10.1038/s41551-017-0178-6.
31.
NajmFJ, StrandC, DonovanKF, et al.Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens. Nat Biotechnol, 2018; 36:179–189. DOI: 10.1038/nbt.4048.
32.
KimHK, MinS, SongM, et al.Deep learning improves prediction of CRISPR-Cpf1 guide RNA activity. Nat Biotechnol, 2018; 36:239–241. DOI: 10.1038/nbt.4061.
33.
PuschmannA, FieselFC, CaulfieldTR, et al.Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. Brain, 2017;140:98–117. DOI: 10.1093/brain/aww261.
34.
ChatterjeeP, JakimoN, JacobsonJM. Minimal PAM specificity of a highly similar SpCas9 ortholog. Sci Adv, 2018; 4:eaau0766. DOI: 10.1126/sciadv.aau0766.
35.
HuJH, MillerSM, GeurtsMH, et al.Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature, 2018; 556:57–63. DOI: 10.1038/nature26155.
36.
HuZ, WangS, ZhangC, et al.A compact Cas9 ortholog from Staphylococcus auricularis (SauriCas9) expands the DNA targeting scope. PLoS Biol, 2020; 18:e3000686. DOI: 10.1371/journal.pbio.3000686.
37.
PauschP, Al-ShayebB, Bisom-RappE, et al.CRISPR-CasPhi from huge phages is a hypercompact genome editor. Science, 2020; 369:333–337. DOI: 10.1126/science.abb1400.
38.
KonermannS, LotfyP, BrideauNJ, et al.Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell, 2018; 173:665–676 e14. DOI: 10.1016/j.cell.2018.02.033.
39.
AbudayyehOO, GootenbergJS, KonermannS, et al.C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science, 2016; 353:aaf5573. DOI: 10.1126/science.aaf5573.
40.
ZhaoX, LiuL, LangJ, et al.A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment. Cancer Lett, 2018; 431:171–181. DOI: 10.1016/j.canlet.2018.05.042.
41.
GaudelliNM, KomorAC, ReesHA, et al.Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature, 2017; 551:464–471. DOI: 10.1038/nature24644.
42.
KomorAC, KimYB, PackerMS, et al.Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 2016; 533:420–424. DOI: 10.1038/nature17946.
43.
KurtIC, ZhouR, IyerS, et al.CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. Nat Biotechnol 2020 Jul 20 [Epub ahead of print]. DOI: 10.1038/s41587-020-0609-x.
44.
ZhaoD, LiJ, LiS, et al.Glycosylase base editors enable C-to-A and C-to-G base changes. Nat Biotechnol 2020 Jul 20 [Epub ahead of print]. DOI: 10.1038/s41587-020-0592-2.
45.
StreckerJ, LadhaA, GardnerZ, et al.RNA-guided DNA insertion with CRISPR-associated transposases. Science, 2019; 365:48–53. DOI: 10.1126/science.aax9181.
46.
KlompeSE, VoPLH, Halpin-HealyTS, et al.Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration. Nature, 2019; 571:219–225. DOI: 10.1038/s41586-019-1323-z.
47.
AnzaloneAV, RandolphPB, DavisJR, et al.Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 2019; 576:149–157. DOI: 10.1038/s41586-019-1711-4.
48.
KuscuC, ParlakM, TufanT, et al.CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations. Nat Methods, 2017; 14:710–712. DOI: 10.1038/nmeth.4327.
49.
BillonP, BryantEE, JosephSA, et al.CRISPR-mediated base editing enables efficient disruption of eukaryotic genes through induction of STOP codons. Mol Cell, 2017; 67:1068–1079.e4. DOI: 10.1016/j.molcel.2017.08.008.
50.
GapinskeM, LuuA, WinterJ, et al.CRISPR-SKIP: programmable gene splicing with single base editors. Genome Biol, 2018; 19:107. DOI: 10.1186/s13059-018-1482-5.
51.
YuanJ, MaY, HuangT, et al.Genetic modulation of RNA splicing with a CRISPR-guided cytidine deaminase. Mol Cell, 2018; 72:380–394.e7. DOI: 10.1016/j.molcel.2018.09.002.
52.
KeoughKC, LyalinaS, OlveraMP, et al.AlleleAnalyzer: a tool for personalized and allele-specific sgRNA design. Genome Biol, 2019; 20:167. DOI: 10.1186/s13059-019-1783-3.
53.
ChenCL, RodigerJ, ChungV, et al.SNP-CRISPR: a web tool for SNP-specific genome editing. G3 (Bethesda), 2020; 10:489–494. DOI: 10.1534/g3.119.400904.
54.
RabinowitzR, AlmogS, Darnell R and OffenD. CrisPam: SNP-derived PAM analysis tool for allele-specific targeting of genetic variants using CRISPR-Cas systems. Front Genet, 2020; 11:851. DOI: 10.3389/fgene.2020.00851.
55.
ScottDA and ZhangF. Implications of human genetic variation in CRISPR-based therapeutic genome editing. Nat Med, 2017; 23:1095–1101. DOI: 10.1038/nm.4377.
56.
LessardS, FrancioliL, AlfoldiJ, et al.Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci. Proc Natl Acad Sci U S A, 2017; 114:E11257–E11266. DOI: 10.1073/pnas.1714640114.
57.
KarczewskiKJ, FrancioliLC, TiaoG, et al.The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 2020; 581:434–443. DOI: 10.1038/s41586-020-2308-7.
58.
HodgkinsA, FarneA, PereraS, et al.WGE: a CRISPR database for genome engineering. Bioinformatics, 2015; 31:3078–3080. DOI: 10.1093/bioinformatics/btv308.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
